September - 2022

Sep 30, 2022

Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy

Maria T Abreu, Julie M Davies, Maria A Quintero, Amber Delmas, Sophia Diaz, Catherine D Martinez, Thomas Venables , Adrian Reich, Gogce Crynen, Amar R Deshpande, David H Kerman, Oriana M Damas, Irina Fernandez, Ana M Santander, Judith Pignac-Kobinger, Juan F Burgueno, Mark S Sundrud Published in Aug 2022, Inflammatory bowel diseases. Abstract Background Inflammatory bowel disease (IBD) involves chronic T cell–mediated inflammatory responses. Vedolizumab (VDZ), a monoclonal an

IBDENC ENC

Sep 27, 2022

Helicobacter bilis Contributes to the Occurrence of Inflammatory Bowel Disease

Helicobacter bilis Contributes to the Occurrence of Inflammatory Bowel Disease by Inducing Host Immune Disorders. Wei Peng, Xinhua Zhao, Xiaoan Li Published in Aug 2022, BioMed research international. Abstract Gut microbiota coevolve with humans to achieve a symbiotic relationship, which ultimately leads to physiological homeostasis. A variety of diseases can occur once this balance is disrupted. Helicobacter bilis (H. bilis) is an opportunistic pathogen in humans, triggering

IBDENC ENC

Sep 23, 2022

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review

Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Kristine Paridaens, Fernando Magro, Silvio Danese, Laurent Peyrin-Biroulet Published in Aug 2022, United European gastroenterology journal. Abstract We performed a systematic review to investigate the definition of mild to moderate active ulcerative colitis (UC), and to describe predictors of good response to treatment in clinical trials assessing 5-ASA and/or budesonide. Thirty-nine randomized controlled trials were include

IBDENC ENC

Sep 22, 2022

An autologous colonic organoid-derived monolayer model to study immune

An autologous colonic organoid-derived monolayer model to study immune: bacterial interactions in Crohn's disease patients. Hamish CK Angus, Paulo CM Urbano, Gemma A Laws, Shijun Fan, Safina Gadeock, Michael Schultz, Grant Butt, Andrew J Highton, Roslyn A Kemp Published in Aug 2022, Clinical & translational immunology. Abstract Objectives Crohn's disease (CD) initiation and pathogenesis are believed to involve an environmental trigger in a genetically susceptible person that

IBDENC ENC

Sep 20, 2022

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Peeyush Kumar, Sudheer K Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet

IBDENC ENC

Sep 17, 2022

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the Immunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study. Neil Chanchlani, Simeng Lin, Marcus K Auth, Chai Leng Lee, Helena Robbins, Shi Looi, Senthil V Murugesan, Tom Riley, Cathryn Preston, Sophie Stephenson, Wendy Cardozo, Sunil A Sonwalkar, Mohammed Allah-Ditta, Lynne Mansfield, Dharmaraj Durai, Mark Baker,

IBDENC ENC

Sep 16, 2022

Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy

IBDENC ENC

Sep 14, 2022

Colorectal cancer in elderly-onset inflammatory bowel disease

Colorectal cancer in elderly-onset inflammatory bowel disease: a 1969–2017 Scandinavian register-based cohort study. Åsa H Everhov, Rune Erichsen, Jacob Järås, Lars Pedersen, Jonas Halfvarson, Johan Askling, Anders Ekbom, Jonas F Ludvigsson, Henrik Toft Sørensen, Ola Olén Published in Aug 2022, Alimentary pharmacology & therapeutics. Summary Background Previous research indicates that the increased relative risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) i

IBDENC ENC

Sep 9, 2022

Proposal of novel staging system CNM to predict postoperative recurrence of Crohn's disease

Proposal of novel staging system CNM (Crohn's primary site, nodes, mesentery) to predict postoperative recurrence of Crohn's disease Guduru Venkat Rao, Partha Pal, Anuradha Sekaran, Pradeep Rebala, Manu Tandan, D Nageshwar Reddy Published in Aug 2022, Intestinal research. Abstract After oncologic resection, histological grading and staging of the tumor give important prognostic information about the future risk of recurrence and hence influence the subsequent management plan.

IBDENC ENC

Sep 9, 2022

Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel

Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Jordi Rimola, Joana Torres, Shankar Kumar, Stuart A Taylor, Torsten Kucharzik Published in Aug 2022, GUT. Abstract Endoscopy remains the reference standard for the diagnosis and assessment of patients with inflammatory bowel disease (IBD), but it has several important limitations. Cross-sectional imaging techniques such as magnetic resonance enterography (MRE) and intestin

IBDENC ENC

Sep 6, 2022

Role of Interventional IBD in Management of Ulcerative Colitis(UC)

Role of Interventional IBD in Management of Ulcerative Colitis(UC)-Associated Neoplasia and Post-Operative Pouch Complications in UC: A Systematic Review. Partha Pal, Rupa Banerjee, Mohan Ramchandani, Zaheer Nabi, Duvvuru Nageshwar Reddy and Manu Tandan Published in Aug 2022, Intestinal research. Abstract Interventional inflammatory bowel disease (IIBD) is going to play a major role in complex IBD including ulcerative-colitis associated neoplasia (UCAN) and postoperative comp

IBDENC ENC

Sep 3, 2022

Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis

Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice. Masataka Masuda, Norimasa Fukata, Yasuki Sano, Shuhei Nishimon, Mamiko Aoi, Takashi Tomiyama, Toshiro Fukui, Mika Omiya, Kazuichi Okazaki, Makoto Naganuma Published in Aug 2022, Journal of Gastroenterology and Hepatology. Abstract Background and Aim Trends in steroid use and the effects of the initial dose, duration of use, and tapering schedule on clinical efficacy

The Mission

Key Opinion Leaders

International

Advisory Board

Initiatives

Discuss a case

Journal Scan

Latest News

Education Hub

Gallery